Preview Newsletter
XARELTO Media Monitoring Week of 2/20/15
-
Lead Counsel Appointed in National Xarelto Lawsuits
Feb 19, 2015 | PR Web
By Onder Law Firm
Attorneys representing clients in Xarelto lawsuits as part of Xarelto (Rivaroxaban) Products Liability Litigation (MDL No. 2592) for the Onder Law Firm announce the appointment of counsel to the Plaintiffs' Steering Committee. According to a recent court document, Pretrial Order #7, the Plaintiffs' Steering Committee was appointed on February 9, 2015. -
Xarelto Attorneys at Bernstein Liebhard LLP Comment on Survey Detailing Cardiologists’ Attitude Towards New-Generation Blood Thinners
Feb 19, 2015 | PR Web
By Bernstein Liebhard LLP
The Xarelto attorneys at Bernstein Liebhard LLP note that a survey conducted this month by the Cardiovascular Institute of Philadelphia produced interesting results regarding the attitude of cardiologists towards new-generation blood thinners. According to the Philadelphia Inquirer, while the physicians were generally pleased that alternatives to warfarin are now available, they expressed concern that there is currently no approved antidote to reverse unwanted internal bleeding that sometimes occurs with Xarelto and other anticoagulants. Warfarin bleeding, by contrast, can be stopped via an injection of vitamin K. -
Xarelto Lawyers at Bernstein Liebhard LLP Comment on New Report Detailing Risks Potentially Associated with Xarelto and Other New Blood Thinners
Feb 14, 2015 | PR Web
By Bernstein Liebhard LLP
The Xarelto lawyers at Bernstein Liebhard LLP note that the Philadelphia Inquirer recently published a report detailing the risks associated with new-generation blood-thinners like Xarelto. Among other things, the article cites a Xarelto patient who had to stop taking the medication after she experienced serious bleeding complications. The report also notes that it and other new-generation anticoagulants were marketed as superior alternatives to warfarin, a blood thinner that has been in use since the 1950s. However, Xarelto and other recent drugs have raised concerns because, unlike warfarin, there are currently no approved reversal agents to stop the internal bleeding that is sometimes associated with their use. -
Xarelto Bleedout: Where Is the Exit Strategy?
Feb 18, 2015 | Lawyers and Settlements
By Gordon Gibb
In life, it is always good to prepare well. Know where you’re going. Have a plan. Having said that, a good plan always includes an exit strategy in case something goes wrong. In case the original decision proved to be the wrong one. This is something we tell our kids, our business partners and ourselves. Plan for moving forward, but always have a way out. If the joke is bombing for the comedian, you better have an exit strategy so you can move beyond it, or you’ll soon be banished from the stage. So why is there no exit strategy for a Xarelto Bleeding Issue? -
Xarelto Drug Causes Irreversible Internal Bleeding
Feb 18, 2015 | Houssiere, Durant & Houssiere LLP
FDA has issued a warning of increased Thrombotic Event (Bleeding and Hemorrhage)! Xarelto is prescribed to prevent strokes in people with arterial fibrillation; as a treatment for deep vein thrombosis and pulmonary embolism; it was first to prevent deep thrombosis in patients undergoing hip or knee replacement surgery. -
XARELTO Bleeding Lawsuit Update
Feb 17, 2015 | American Injury Attorney Group
By Anthony Johnson
On January 22, 2015, a woman filed a Xarelto bleeding lawsuit against the drug’s manufacturers Bayer Healthcare Pharmaceuticals and Janssen Research and Development. The woman claims that during clinical trials before Xarelto was released, the companies learned of a potentially increased risk of bleeding from certain parts of the body. -
Xarelto Bleeding Risk Inhibits User’s Ability to Enjoy Life, Report Suggests
Feb 17, 2015 | Bernstein Liebhard LLP
Life on a blood-thinning medication may lead to cutbacks made to lower the risk of problems alleged in numerous Xarelto lawsuits, but may result in a user’s diminished quality of life, Philly.com reports. -
Increased Xarelto Concerning
Feb 17, 2015 | The Parian Law Firm, LLC
By Cade Parian
It appears that big business profit is overtaking the safety and well-being of Americans again. Despite hundreds of lawsuits being filed in two federal courts, Bayer Pharmaceuticals and Johnson & Johnson, the maker and marketer of Xarelto, have begun a study to test the effects of Xarelto on stroke patients. Keep in mind that Xarelto raked in over $1.5 billion in sales just this past year despite thousands of reports of uncontrolled bleeds from the drug. -
Knee Replacement Patient Alleges Xarelto Bleeding Incident
Feb 16, 2015 | Top Class Actions
By Robert Boumis
A couple from Ohio has filed a Xarelto lawsuit against Janssen Pharmaceuticals, arguing that the drug maker’s blood thinner caused life-threatening bleeding side effects. -
Xarelto Internal Bleeding Antidote: Too Little Too Late?
Feb 13, 2015 | Van Wey Law PLLC
Xarelto is a popular blood thinner that you may have seen recently advertised on television. It is prescribed to patients for the prevention of blood clots and strokes, and for patients suffering with atrial fibrillation. What many people may not know is thatXarelto can also cause irreversible internal bleeding, often resulting in hospitalizations, serious injury, or even death. -
Blood thinner Xarelto poses deadly threat of internal bleeding
Feb 13, 2015 | The Legal Examiner
By Emily Beeson
*Note: This article is sponsored by Egerton & Associates. The use of blood thinners is common in our society to prevent blood clotting and strokes, both as a daily treatment and after hip or knee surgery. For years, Warfarin and Coumadin dominated the market, with minimal negative side effects for patients. -
Leadership Roles Appointed in Xarelto MDL
Feb 17, 2015 | The Schmidt Law LLP
The judge overseeing all federalXarelto lawsuits has appointed twelve attorneys, including two co-lead counsel, to leadership roles in the litigation. -
Xarelto Lawsuits Gain Plaintiffs’ Steering Committee
Feb 16, 2015 | Drug Reporter
By Jacky Gale
*Note: This site is sponsored by Eisbrouch Marsh, LLC. To date, about 100 Xarelto lawsuits filed in federal court systems have been centralized into a multidistrict litigation (MDL), which is proceeding in the U.S. District Court for the Eastern District of Louisiana. -
Xarelto Lawsuit – Lead Lawyers Appointed
Feb 16, 2015 | The Legal Examiner
By Robert Blanchard
In a recent Federal Court Order, lawyers from around the country were selected to head up the many lawsuits filed in the U.S. involving bleeding deaths and injuries from the drug Xarelto. -
Bayer, J&J Begin Xarelto Study, Bleeding Lawsuits Consolidated
Feb 17, 2015 | Drug Watch
By Michelle Llamas
*Note: This site is sponsored by The Peterson Firm, LLP. Bayer and Johnson & Johnson announced late last month they will push for additional Food and Drug Administration (FDA) approvals for the blockbuster blood-thinner Xarelto, even as two U.S. courts consolidated bleeding lawsuits against both companies. -
Has XARELTO Litigation Been Consolidated?
Feb 13, 2015 | Zoll, Kranz & Borgess LLC
*Note: Zoll, Kranz & Borgess LLC has embedded from their personal YouTube handle a video on XARELTO and its alleged safety concerns. A video of the segment is available at https://www.youtube.com/watch?v=4nryxrspvC8. The drug Xarelto (rivaroxaban) is a blood thinner commonly used to treat atrial fibrillation, and on patients who have had hip or knee replacement surgery. However, it has been linked to uncontrolled internal bleeding, particularly gastrointestinal bleeding events. -
XARELTO Cases Adding Plaintiffs
Feb 14, 2015 | Meyerkord & Meyerkord LLC
Janssen Research and Development and Bayer Healthcare Pharmaceuticals are continuing to be named in lawsuits for their negligence by users of the drug Xarelto. The defendants are the makers of the anticoagulant, Xarelto, and are claiming their product is the best anticoagulant in the market due to its' convenience. Xarelto lawsuits have recently been consolidated due to the growing number of cases filed.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blogs
Steering Committee
MDL Consolidation
Full Text of Stories Below
-
Lead Counsel Appointed in National Xarelto Lawsuits
Feb 19, 2015 | PR Web
By Onder Law Firm
Attorneys representing clients in Xarelto lawsuits as part of Xarelto (Rivaroxaban) Products Liability Litigation (MDL No. 2592) for the Onder Law Firm announce the appointment of counsel to the Plaintiffs' Steering Committee. According to a recent court document, Pretrial Order #7, the Plaintiffs' Steering Committee was appointed on February 9, 2015.
From the group of applicants, the Court selected the following members, according to court documents: Andy Birchfield of Montgomery, Alabama; Brian Barr of Pensacola, Florida; Russell Abney of Atlanta, Georgia; Mark Alan Hoffman of Philadelphia, Pennsylvania; Bradley Honnold of Leawood, Kansas; Frederick Longer of Philadelphia, Pennsylvania; Sindhu Daniel of Newark, New Jersey; Dianne Nast of Philadelphia, Pennsylvania; Roger Denton of St. Louis, Missouri; Neil Overholtz of Pensacola, Florida; Michael Goetz of Tampa, Florida; and Ellen Relkin of New York, New York. Birchfield and Barr have been appointed Co-Lead Counsel, according to the court documents. Additionally, Leonard Davis and Gerald Meunier are set as the Co-Plaintiffs’ Liaison Counsel. Each of these appointments is for one year, according to the Pretrial Order.
The Co-Plaintiffs’ Liaisons and the Co-Lead Counsel together comprise the Plaintiffs’ Steering Executive Committee, who are charged with coordinating the Steering Committee, scheduling meetings, keeping minutes, attending status conferences, and other administrative functions, according to the court document. The appointment of the Plaintiffs’ Steering Committee is a routine early pretrial proceeding, which allows for Discovery to commence, according to the Onder Law Firm.
Attorneys representing clients nationwide in Xarelto lawsuits are still accepting Xarelto claims for possible inclusion in the MDL. Xarelto lawsuits were consolidated in Louisiana during December of 2014 under the name Xarelto (Rivaroxaban) Products Liability Litigation (MDL No. 2592), according to court documents from the Judicial Panel on Multidistrict Litigation. Plaintiffs in Xarelto lawsuits allege that the Xarelto’s label did not adequately warn consumers of the potential for serious side effects such as internal bleeding, according to court documents.
Xarelto lawyers representing clients nationwide for the Onder Law Firm are now accepting claims from individuals and families of individuals who suffered from severe internal bleeding or hemorrhagic stroke and also have a history of taking Xarelto. Lawyers are investigating these inquiries for possible Xarelto lawsuits. The Onder Law Firm is renowned for its achievements in product and consumer safety litigation, with a strong track record of winning meaningful settlements for clients. The firm is nationally-renowned for its work on window blind strangulation, and has notable expertise in fighting on behalf of individuals against powerful corporations. Individuals and the family members of individuals who have suffered from internal bleeding and have taken Xarelto are eligible for a no-cost, no-obligation Xarelto lawsuit case review, and may contact the firm through its Xarelto Contingency Lawsuit website. The firm provides information on bleeding warnings and Xarelto lawsuit news.
-
Feb 19, 2015 | PR Web
By Bernstein Liebhard LLP
The Xarelto attorneys at Bernstein Liebhard LLP note that a survey conducted this month by the Cardiovascular Institute of Philadelphia produced interesting results regarding the attitude of cardiologists towards new-generation blood thinners. According to the Philadelphia Inquirer, while the physicians were generally pleased that alternatives to warfarin are now available, they expressed concern that there is currently no approved antidote to reverse unwanted internal bleeding that sometimes occurs with Xarelto and other anticoagulants. Warfarin bleeding, by contrast, can be stopped via an injection of vitamin K.*
“The results of this survey are notable, as hundreds of people are currently pursuing Xarelto lawsuits in U.S. courts that seek compensation for internal bleeding and other complications allegedly related to its use. These claims also raise questions about the lack of a reversal agent for Xarelto bleeding. This issue is certainly one that should be discussed with patients before the drug is prescribed,” said Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently representing a number of clients who have filed Xarelto lawsuits, and continues to offer free, no-obligation legal reviews to individuals who allegedly suffered serious injuries from the blood thinner, including uncontrollable bleeding, strokes, deep vein thrombosis or pulmonary embolism.
Xarelto Litigation
Xarelto is a new -generation blood thinner that was first approved by the U.S. Food & Drug Administration in 2011. The medication is currently indicated to prevent strokes in people with atrial fibrillation; as a treatment for deep vein thrombosis and pulmonary embolism; and to prevent deep vein thrombosis in patients undergoing hip or knee replacement surgery.** During its first full year on the market, Xarelto was named in 2,081 adverse event reports submitted to the FDA, including at least 151 deaths. Warfarin, which has been in use since the 1950s, was named in only 861 adverse event reports, including 56 fatalities.***Court documents indicate that more than 200 Xarelto lawsuits are currently pending in a federal multidistrict litigation now underway in the U.S. District Court, Eastern District of Louisiana, all of which put forth similar allegations regarding the drug’s association with uncontrollable bleeding, hemorrhagic stroke, deep vein thrombosis, pulmonary embolism, and other life-threatening complications. Among other things, plaintiffs assert that the manufacturers of Xarelto wrongly marketed the drug as superior to warfarin, given the lack of an approved antidote to stop internal bleeding. In Re: Xarelto Products Liability Litigation, No. 2592)
Xarelto patients who allegedly experienced life-threatening episodes of internal bleeding and other complications related to its use may be entitled to take legal action against the drug’s manufacturers. Learn more about filing a Xarelto lawsuit by visiting Bernstein Liebhard LLP’s website, or by calling 800-511-5092 to schedule a free, no obligation case review.
-
Feb 14, 2015 | PR Web
By Bernstein Liebhard LLP
The Xarelto lawyers (http://www.xareltolawsuit2015.com/xarelto-lawyer/) at Bernstein Liebhard LLP note that the Philadelphia Inquirer recently published a report detailing the risks associated with new-generation blood-thinners like Xarelto. Among other things, the article cites a Xarelto patient who had to stop taking the medication after she experienced serious bleeding complications. The report also notes that it and other new-generation anticoagulants were marketed as superior alternatives to warfarin, a blood thinner that has been in use since the 1950s. However, Xarelto and other recent drugs have raised concerns because, unlike warfarin, there are currently no approved reversal agents to stop the internal bleeding that is sometimes associated with their use.*
“The Inquirer also notes the growing product liability litigation involving Xarelto. Our Firm is currently representing Xarelto lawsuit plaintiffs who allegedly experienced serious internal bleeding complications similar to those detailed in this report,” said Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free, no-obligation Xarelto case reviews to people who allegedly suffered serious injuries from the blood thinner, including uncontrollable bleeding, strokes, deep vein thrombosis or pulmonary embolism.
Xarelto Lawsuit Allegations
Xarelto (rivaroxaban) was approved by the U.S. Food & Drug Administration in 2011, and is currently indicated to prevent strokes in people with atrial fibrillation; as a treatment for deep vein thrombosis and pulmonary embolism; and to prevent deep vein thrombosis in patients undergoing hip or knee replacement surgery.**Court documents indicate that dozens of federally-filed Xarelto lawsuits have been consolidated in a multidistrict litigation now underway in the U.S. District Court, Eastern District of Louisiana, all of which were brought on behalf of individuals who allegedly experienced uncontrollable internal bleeding and other dangerous side effects due to their use of Xarelto. Among other things, these lawsuits allege the drugs’ manufacturers wrongly marketed Xarelto as a superior alternative to warfarin, noting that bleeding caused by the older drug can be stopped via the administration of vitamin K. The lawsuits also claim that the drug makers should have recommended blood monitoring for Xarelto patients, so that physicians could adjust dosage to avoid high concentrations that have the potential to lead to life-threatening internal hemorrhaging. (In Re: Xarelto Products Liability Litigation, No. 2592)
Xarelto patients who were allegedly harmed by the blood thinner may be entitled to recover compensation for medical bills, lost wages, pain and suffering, and more. To learn more about filing a Xarelto lawsuit, please visit Bernstein Liebhard LLPs website, or call 800-511-5092 to schedule a free, no obligation case review.
-
Xarelto Bleedout: Where Is the Exit Strategy?
Feb 18, 2015 | Lawyers and Settlements
By Gordon Gibb
In life, it is always good to prepare well. Know where you’re going. Have a plan. Having said that, a good plan always includes an exit strategy in case something goes wrong. In case the original decision proved to be the wrong one. This is something we tell our kids, our business partners and ourselves. Plan for moving forward, but always have a way out. If the joke is bombing for the comedian, you better have an exit strategy so you can move beyond it, or you’ll soon be banished from the stage. So why is there no exit strategy for a Xarelto Bleeding Issue?
Critics go one further: why was Rivaroxaban (Xarelto) approved in the first place without an antidote? One of the so-called heirs apparent to Coumadin (warfarin), a heritage anticoagulant that always featured a way to reverse its blood-thinning properties, Xarelto has no such escape clause or exit strategy.
The manufacturers are diligently working on one. That said, it seems Xarelto (Rivaroxaban) was deemed worthy of submission to the US Food and Drug Administration (FDA) for approval - and was duly approved - in spite of that important missing feature. In the meantime, plaintiffs are coming forward with legal challenges surrounding the safety and efficacy of Xarelto over the interim, following Xarelto Bleeding complications.
One of the more recent Xarelto Side Effects lawsuits was filed two days before Christmas last year by a plaintiff in West Virginia. Nova D. Rose alleges in her Xarelto lawsuit she filed as a co-plaintiff with her husband William H. Rose that she suffered a severe gastrointestinal bleed following her use of Xarelto. Defendants include Janssen Research & Development LLC; Janssen Ortho LLC; Janssen Pharmaceuticals, Inc.; Bayer Healthcare Pharmaceuticals, Inc.; Bayer Pharma AG; Bayer Corporation; Bayer HealthCare LLC; Bayer Healthcare AG; and Bayer AG.
Rose asserts that defendants knew or would have known that Xarelto could foster serious internal bleeding.
Of course, it should be noted that most blood thinners pose that risk. Thinning the blood as a means to help prevent blood clots and strokes carries a risk for bleeding events that can be more difficult to control when compared with similar bleeds when the blood is in its normal state.
Careful monitoring procedures can help prevent unexpected and potentially serious hemorrhages and bleeding events. Monitoring is a necessary byproduct of Coumadin use, the gold standard for blood thinners for the past half century. Coumadin (warfarin) has been considered safe and effective - but also a hassle given strict, ongoing monitoring and diet restrictions.
Then along comes Xarelto (and a competitor, Pradaxa) that is promoted as requiring less stringent monitoring, and therefore affords added convenience. Blood thinners such as Xarelto that require less physician and lab time for monitoring have been sought for years.
But there is one big difference between Xarelto and Coumadin (warfarin), say critics.
There is no way to effectively reverse a Xarelto Bleeding Issue once it starts.
With Coumadin, strict monitoring helps mitigate or minimize the risk for hemorrhage. Were one to start, warfarin responds to the introduction of vitamin K into the bloodstream. Provided vitamin K can be administered quickly and expeditiously, the blood-thinning properties of warfarin are reversed, helping to mitigate the hemorrhage by allowing the blood to once again clot.Xarelto was brought to market without such an escape clause or exit strategy in place. Not only are Xarelto patients monitored less carefully than those taking Coumadin, there is no antidote once a Xarelto Bleedout occurs.
It translates to a double-edged sword that can result - and has, for some - in Xarelto Death.
Given the aging American population and the demand on an overtaxed health care system, it’s expected that Xarelto Side Effects will drive an increasing level of litigation as patients find they are having to deal with more than they bargained for with regard to new-age products that are billed as superior to heritage products of old.
The Xarelto lawsuit is Rose et al v. Janssen Research & Development LLC et al, Case number 2:2014cv30672, filed December 23, 2014 in US District Court in the Southern District of West Virginia. -
Xarelto Drug Causes Irreversible Internal Bleeding
Feb 18, 2015 | Houssiere, Durant & Houssiere LLP
FDA has issued a warning of increased Thrombotic Event (Bleeding and Hemorrhage)! Xarelto is prescribed to prevent strokes in people with arterial fibrillation; as a treatment for deep vein thrombosis and pulmonary embolism; it was first to prevent deep thrombosis in patients undergoing hip or knee replacement surgery.
Xarelto Blood Thinner is under investigation by the FDA. The FDA has received 68– adverse reports related to the patients using the blood thinner. Doctors state there is no way to reverse the effects of this dangerous drug. The complaints point out that while warfain bleeding can be reversed via the administration of vitamin K, there is no antidote to stop the bleeding that sometimes occurs with Xarelto. Patients can develop internal bleeding. Xarelto patients who experienced uncontrollable internal GI bleeding, deep vein thrombosis, pulmonary embolism, or other serious complication may be able to pursue a legal claim against the drug manufacturers.
-
XARELTO Bleeding Lawsuit Update
Feb 17, 2015 | American Injury Attorney Group
By Anthony Johnson
On January 22, 2015, a woman filed a Xarelto bleeding lawsuit against the drug’s manufacturers Bayer Healthcare Pharmaceuticals and Janssen Research and Development. The woman claims that during clinical trials before Xarelto was released, the companies learned of a potentially increased risk of bleeding from certain parts of the body.
If you have suffered from bleeding complications after taking Xarelto, call the American Injury Attorney Group today for more information. We offer free, no obligation consultations and can connect you with an experienced Xarelto bleeding lawsuit attorney.
What is Xarelto?
Xarelto, a well-known blood thinner designed to prevent strokes, has recently been linked to internal bleeding and other severe health complications. Xarelto is manufactured and marketed as a safe and effective drug designed to reduce the risk of blood clots, pulmonary embolisms, heart attacks, strokes, and death. It was first released in the U.S. in 2011 after the drug’s makers conducted a series of clinical trials.
Xarelto Bleeding Lawsuit Overview
Claims against Bayer and Janssen allege that the companies used the results of the Einstein studies, the Record studies, and the Rocket AF study to promote the drug in commercials and on the internet, emphasizing the positive results. However, these promotional materials allegedly failed to highlight the increased risk of internal bleeding, gastrointestinal bleeding, and other bleeding complications in Xarelto patients.
Bayer and Janssen reportedly spent $11 million to promote the medication and grossed more than $582 million in sales in 2011. Xarelto patients across the U.S. claim the drug makers failed to disclose Xarelto’s anti-coagulation effects and overstated its effectiveness. The plaintiff in the recently filed Xarelto bleeding lawsuit is seeking over $4.35 million in damages.
In 2012, approximately 2,081 adverse event reports were submitted to the U.S. Food and Drug Administration involving Xarelto, and 151 of those involved the death of a patient. Those pursuing claims for Xarelto bleeding allege they suffered from severe personal injuries, including a diminished enjoyment of life, mental anguish, physical pain, lost earnings, and incurred medical costs.
Claimants also allege the manufacturers’ negligence caused the resulting internal bleeding injuries that the companies failed to investigate and fully define Xarelto’s safety and effectiveness and that they failed to provide adequate warnings to both the public and healthcare communities. Other allegations include claims of strict products liability, fraudulent misrepresentation, negligent misrepresentation, common law fraud, negligent infliction of emotional distress, and intentional infliction of emotional distress.
If you have experienced rectal bleeding, brain hemorrhaging, intestinal bleeding, or lost a loved one due to bleeding complications that may have been caused by use of Xarelto., you should consider seeking legal counsel While adverse complications that can be caused by other blood thinners such as warfarin can be reversed with a shot of vitamin K or other antidote, there is presently no known antidote for Xarelto.
Learn More about a Xarelto Bleeding Lawsuit
Contact the American Injury Attorney Group if you took Xarelto and suffered from internal bleeding, gastrointestinal bleeding, or other types of bleeding. We can answer your questions at no out-of-pocket cost to you, and we can refer you to an affiliated attorney who can file a Xarelto bleeding lawsuit on your behalf.
-
Xarelto Bleeding Risk Inhibits User’s Ability to Enjoy Life, Report Suggests
Feb 17, 2015 | Bernstein Liebhard LLP
Life on a blood-thinning medication may lead to cutbacks made to lower the risk of problems alleged in numerous Xarelto lawsuits, but may result in a user’s diminished quality of life, Philly.com reports.
According to an article on January 26th, one New Jersey man stopped woodworking because of its proximity to sharp tools, and now has to keep a special powder in tow that can be applied to bad cuts that could otherwise ignite life-threatening episodes of internal bleeding. Another patient put away his surfboard after his doctor warned him of ramifications that could occur if he hit his head, and a woman also quoted in the report had the misfortune of actually suffering this side effect, which is common to several new-generation anticoagulants in the fall of 2014—a year after she began taking Xarelto. She woke up to severe rectal bleeding that landed her in the emergency room, and later three days in the hospital.
“It’s bright red, and it won’t stop,” remembers the patient, who promptly stopped taking the medication after her Xarelto internal bleeding experience.
Xarelto Touted for Convenience by Janssen, Bayer
Xarelto was approved in 2011 by the U.S. Food and Drug Administration (FDA) and is jointly manufactured by Johnson & Johnson’s Janssen unit and Bayer Healthcare. Together, these companies have marketed the drug since then as a convenient alternative to the older-generation anticoagulant, warfarin. Unlike that medication, which requires patients to undergo routine blood level monitoring every couple weeks and adhere to certain dietary modifications, which Xarelto users don’t need to do.
The medication may have serious consequences, however, if an individual sustains an episode of internal bleeding. There is no available reversal agent to stop this complication once it begins, which could increase the risk for a life-threatening bleed.
Individuals who experience internal bleeding caused by Pradaxa may suffer a similar fate, as this medication is part of the same class and also has no antidote to stop hemorrhaging.
Lawsuits involving both these products are continuing to be filed in two separate multidistrict litigations now underway in the U.S. In December 2014, claims involving Xarelto were transferred to a federal proceeding in the U.S. District Court, Eastern District of Louisiana. Meanwhile, Pradaxa suits have been centralized in a litigation established in the Southern District of Illinois.
-
Feb 17, 2015 | The Parian Law Firm, LLC
By Cade Parian
It appears that big business profit is overtaking the safety and well-being of Americans again. Despite hundreds of lawsuits being filed in two federal courts, Bayer Pharmaceuticals and Johnson & Johnson, the maker and marketer of Xarelto, have begun a study to test the effects of Xarelto on stroke patients.
Keep in mind that Xarelto raked in over $1.5 billion in sales just this past year despite thousands of reports of uncontrolled bleeds from the drug.
There is no known remedy that will stop an uncontrolled bleed when the patient is taking Xarelto. Nevertheless, Bayer and J&J see it fit to continue marketing and selling their highly profitable, yet extremely dangerous, Xarelto product.The Atlanta Xarelto Attorneys of The Parian Law Firm, LLC Take a Stand Against Dangerous Drug Manufacturers
There is absolutely no reason for a known dangerous drug such as Xarelto to be introduced to even more patients. Xarelto was billed as a superior alternative to Coumadin; however, it was little known that it may cause injury or death due to hemorrhaging or severe bleeding. Despite knowing this fact now, Bayer & J&J want to introduce this drug to stroke patients as a replacement for aspirin. Now is the time to let Xarelto caused injuries and deaths be known. If you or someone you know has seen first-hand the dangerous side effects that Xarelto causes, call the Georgia Xarelto Attorneys of The Parian Law Firm, LLC at (770) 727-5550 to discuss your possible claims.
-
Knee Replacement Patient Alleges Xarelto Bleeding Incident
Feb 16, 2015 | Top Class Actions
By Robert Boumis
A couple from Ohio has filed a Xarelto lawsuit against Janssen Pharmaceuticals, arguing that the drug maker’s blood thinner caused life-threatening bleeding side effects.
This Xarelto lawsuit was filed by plaintiffs Charlotte S. and Gerald S. According to the couple, Charlotte was prescribed the drug in February 2012 after she had knee surgery.
This surgery put Charlotte at risk for deep vein thrombosis and pulmonary embolisms, two possible blood-clot related complications. Xarelto was supposed to reduce her risk of these complications from her knee surgery.
However, the Xarelto lawsuit asserts that Charlotte suffered from uncontrolled bleeding from Xarelto on Feb. 23, 2012, mere days after she began taking Xarelto. This was a medical emergency and required intensive medical care to save her from bleeding to death.
Xarelto is a type of drug called an anticoagulant or blood thinner. Anticoagulants are designed to make it harder for patients to form blood clots. While blood clots are a normal part of the healing process, it can misfire.
When a blood clot forms within the body, it can lodge within the blood vessels that feed critical tissues, including the heart, lungs and brain. This would cause certain types of heart attacks, pulmonary embolisms, and stroke.
Drugs like Xarelto are designed to reduce the risk of these conditions. But all anticoagulants carry the risk of working too well and resulting in uncontrollable bleeding, and Xarelto lawsuits allege that Xarelto and other newer anticoagulants carry the risk of working too well.
All anticoagulants carry the risk of causing uncontrolled bleeding. When this happens, the patient loses the ability to form blood clots, and they can lose a life-threatening amount of blood from a very minor injury, including internal injuries. This may take the form of gastrointestinal bleeding or pulmonary bleeding.
But Xarelto lawsuits like this one allege that Xarelto and other newer-generation blood thinners are particularly dangerous for several reasons. First, Xarelto does not have a known reversal agent.
Older anticoagulants like Warfarin can be “turned off” in an emergency uncontrolled bleeding incident. The way this works is that when there’s an uncontrolled bleeding event, patients on Warfarin can be given a high dose of vitamin K to let the patient’s blood clot.
Additionally, older drugs like Warfarin require that patients routinely test their blood to make sure the drug is working right. Despite some research that Xarelto patients could benefit from such as blood testing, the makers of Xarelto have advertised Xarelto as not requiring blood tests.
The Xarelto Uncontrollable Bleeding Lawsuit is Case No. 1:15-cv-28, in the U.S. District Court for the Southern District of Ohio, Cincinnati Division.
-
Xarelto Internal Bleeding Antidote: Too Little Too Late?
Feb 13, 2015 | Van Wey Law PLLC
Xarelto is a popular blood thinner that you may have seen recently advertised on television. It is prescribed to patients for the prevention of blood clots and strokes, and for patients suffering with atrial fibrillation. What many people may not know is thatXarelto can also cause irreversible internal bleeding, often resulting in hospitalizations, serious injury, or even death.
Xarelto as Dangerous as Pradaxa
You may be aware by now that Pradaxa is known to have caused devastating internal bleeding injuries and deaths for many unfortunate victims who were taking the drug, unaware of its dangers. Xarelto, also billion-dollar drug, is just as dangerous. These two anticoagulants (blood thinners), first Pradaxa, followed by Xarelto, were introduced to replace the only blood thinner available for decades, Warfarin, as a more convenient, less obtrusive options for patients requiring a blood thinner.
Warfarin was inconvenient, requiring frequent doctor visits for blood monitoring, dietary changes, and lifestyle changes. It was the most widely used blood thinner for decades until Pradaxa and Xarelto arrived on the market. Big Pharma worked hard for years to develop a newer, less obtrusive drug to take the place of Warfarin. The results of this work are Pradaxa, made by Boehringer Ingelheim, and Xarelto, made by Bayer and Johnson & Johnson.
When Pradaxa hit the market in 2010, it was met with instant success and easily became a blockbuster drug. By 2012, more than 3.7 million Americans had filled prescriptions forPradaxa. Worldwide, the sales were around $210 million.
Vital Information Not Revealed
Boehringer had found its fortune with Pradaxa, but failed to let the medical community and consumers know about a significant factor: There was no antidote for the internal bleeding that could occur in patients using the drug daily. Even minor injuries could land patients in the hospital, leaving doctors helopless, with no way to stop the bleeding until the body was rid of the drug, or the patient had died.
Xarelto is very similar, and also does not have an antidote to stop bleeding events and hemorrhaging in unaware patients. However, the FDA approved it regardless. Even though these two new anticoagulants were significantly more expensive thanWarfarin, users were willing to pay the price in exchange for the convenience of fewer doctor visits and lifestyle changes.
Thousands of Deaths Linked to Pradaxa and Xarelto
The deaths and injuries caused by Pradaxa and Xarelto have resulted in massive litigation against the manufacturers. Patients who have suffered injuries, as well as family members who have lost loved ones as a result of taking these drugs, are angry. They should be. They are seeking justice and compensation from these negligent manufacturers who contributed to the numerous unnecessary, serious injuries and deaths that have occurred, changing lives forever.
In May of 2014, thousands of Pradaxa lawsuits were settled for about $650 million. Though another pharmaceutical company now claims to have developed a drug that can reverse the bleeding effects of Pradaxa and Xarelto, for many it comes too late.
You May Have a Xarelto Lawsuit
Anybody who has suffered serious injury that has left them hospitalized, or lost a loved one due to internal bleeding caused by Xarelto, may be eligible to file a lawsuit against the manufacturer. A lawsuit is sometimes necessary to help you with extensive hospital bills due to frequent hospitalizations, time spent away from work, emotional distress, and even funeral expenses. Sometimes this is the only way for you to get back on your feet again and continue on with your lives as normally as possible.
Our team at Van Wey Law is currently assisting victims throughout the United Stateswho have suffered excessive bleeding, or the loss of a loved one, due to a Xareltointernal bleeding event. Fill out a quick form, or contact our office today if you have any questions about your Xarelto case. We offer free consultations and would love to help you seek the justice you deserve. We want to hold accountable those who are responsible for you injury or loss, who chose to place profits above public safety.
-
Blood thinner Xarelto poses deadly threat of internal bleeding
Feb 13, 2015 | The Legal Examiner
By Emily Beeson
The use of blood thinners is common in our society to prevent blood clotting and strokes, both as a daily treatment and after hip or knee surgery. For years, Warfarin and Coumadin dominated the market, with minimal negative side effects for patients.
In 2011, pharmaceutical giants Johnson & Johnson (JNJ) and Bayer introduced a new blood thinner, Xarelto, and quickly raked in great profits.
The older blood thinners, Warfarin and Coumadin, are generally taken twice a day, and require frequent doctor visits to monitor levels of the medicine in the blood. By taking the pills twice a day, patients maintain a relatively stable amount of the drugs in the body throughout the day. Doctors are able to adjust dosages and avoid serious bleeding episodes by keeping an eye on these levels with regular testing.
Xarelto is marketed as an alternative to the hassle of twice-a-day pills and frequent visits to the doctor’s office. Instead, patients take only one dose of the blood thinner each day. The drug’s website and commercials tout that regular blood monitoring is not required.
Without regular monitoring by a doctor, patients can suffer from preventable bleeding episodes because their dosages are not adjusted as needed. The Food and Drug Administration (FDA) has required Xarelto to change its warning label several times to emphasize the serious side effects that the drug can cause. Still, Xarelto is advertised as not requiring blood monitoring by a doctor.
Xarelto has been causing episodes of severe bleeding in patients who are taking the drug long term, for problems like atrial fibrillation, and in those taking the pill for a short time after surgery. The bleeding can be in the form of a nosebleed that just will not stop, or it can be internal bleeding that you cannot see. Internal bleeding can be fatal if uncontrolled – unlike Warfarin and Coumadin, Xarelto does not have a reversal agent, so once the bleeding starts, it cannot be stopped until the drug is out of the patient’s body.
If you or a loved one has suffered a severe bleeding episode after taking Xarelto, call the lawyers at Egerton & Associates today. We are investigating injuries caused by Xarelto and can help you determine whether you have a case against JNJ and Bayer. Call us at 1-800-800-4LAW or fill out aweb contact form with your questions about Xarelto.
-
Leadership Roles Appointed in Xarelto MDL
Feb 17, 2015 | The Schmidt Law LLP
The judge overseeing all federalXarelto lawsuits has appointed twelve attorneys, including two co-lead counsel, to leadership roles in the litigation.
U.S. District Judge Eldon E. Fallon established the Plaintiffs’ Steering Committee in an order (PDF) filed on February 9.
Attorneys with leadership roles have many responsibilities, including:
Coordinating and conducting all pretrial discovery
Examining witnesses and introducing evidence
Selecting “bellwether” trials
Pursuing settlement options
Communicating pertinent developments to all plaintiffs and their counsel
Other functions as necessaryJudge Fallon oversees about 90 lawsuits involving Xarelto. All of the lawsuits were filed on behalf of people who were seriously injured or died from severe bleeding after taking Xarelto.
Plaintiffs accuse Bayer of downplaying information about its serious bleeding risks, including the risk of fatal bleeding and Xarelto’s lack of a reversal agent.
The litigation is remarkably similar to one involving Pradaxa (dabigatran), a blood-thinner made by Boehringer Ingelheim. Last year, about 4,000 lawsuits settled for $650 million, or about $162,500 per claimant.
Judge Fallon appointed attorney Brian Barr to the co-lead counsel in the Xarelto litigation. He said, “Our experience with litigating the Pradaxa lawsuits (also a blood thinner) will give us a good head start in the discovery process.”
As the Xarelto litigation proceeds, it is likely that attorneys will choose certain cases for “bellwether” trials to go before a jury. If the jury decides to award compensation, it can help attorneys negotiate a settlement or other resolution for lawsuits with similar injuries.Do I have a Xarelto Lawsuit?
The Schmidt Firm, LLP is currently accepting Xarelto induced injury cases in all 50 states. If you or somebody you know has been injured by severe bleeding, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.
-
Xarelto Lawsuits Gain Plaintiffs’ Steering Committee
Feb 16, 2015 | Drug Reporter
By Jacky Gale
To date, about 100 Xarelto lawsuits filed in federal court systems have been centralized into a multidistrict litigation (MDL), which is proceeding in the U.S. District Court for the Eastern District of Louisiana.
Judge Eldon E. Fallon is presiding over the MDL, which was established in December 2014 by the U.S. Judicial Panel on Multidistrict Litigation (JPML). As is typical of MDLs, a great deal of pretrial work must be completed before the first trial against the defendants, Bayer and Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals. The latest update from Eastern Louisiana is the issuance of the seventh pretrial order, which establishes a Plaintiffs’ Steering Committee.Plaintiffs’ Steering Committee
Judge Fallon had received numerous requests for leadership positions by various attorneys for the plaintiffs. On February 9, 2015, his new order appointed 12 attorneys to the Plaintiffs’ Steering Committee, which includes two co-lead counsels.
As part of the committee, these Xarelto attorneys are expected to fulfill various responsibilities throughout the course of pretrial discovery. First, they are responsible for initiating, coordinating, and conducting all aspects of pretrial discovery on behalf of all of the plaintiffs. They must also develop proposed schedules for various discovery actions. The attorneys will need to issue discovery requests, motions, and subpoenas for the benefit of all of the plaintiffs.
Periodically, hearings and meetings will be called for purposes such as coordinating responses to requests or questions, initiating proposals or joint briefs, introducing evidence, and examining witnesses. For the trials themselves, the attorneys on the Plaintiffs’ Steering Committee will be responsible for coordinating the selection and management of common issues and bellwether trials. They will also prepare trial packages that may be used for any trial in the MDL, including those that are remanded back to their home districts following the conclusion of the bellwether trials.Xarelto lawsuits allege uncontrolled bleeding
Given the accusations leveled in Xarelto cases, it is expected that the involved parties will question experts such as doctors and employees of the pharmaceutical giant. The counsel for the plaintiffs will attempt to prove that the defendants knew or should have known of the serious bleeding risks of Xarelto(rivaroxaban), but that they withheld important safety information.
All of the plaintiffs in the MDL make similar allegations and statements of fact. The plaintiffs were prescribed the blood-thinning medication, which was first introduced into the stream of commerce in 2011 as a proposed alternative to the gold standard of blood thinners, Coumadin (warfarin). These drugs interfere with the body’s ability to clot blood, which may help reduce the risk of a life-threatening stroke among patients with atrial fibrillation. All drugs of this type carry the risk of abnormal bleeding. However, research has shown that the newer generation of blood thinners, including Xarelto, carriesrisks that have the potential to be fatal.
When a patient on Coumadin begins to bleed uncontrollably, doctors can administer a therapeutic dose of vitamin K to reverse the effects of the drug and allow the blood to clot. However, this antidote does not work for Xarelto, and in fact, the drug has no available reversal agent whatsoever.
Although the MDL currently contains a relatively small number of plaintiffs, it is expected that many more will step forward in the coming months and years, as the link between Xarelto and life-threatening bleeding becomes more widely known.
-
Xarelto Lawsuit – Lead Lawyers Appointed
Feb 16, 2015 | The Legal Examiner
By Robert Blanchard
In a recent Federal Court Order, lawyers from around the country were selected to head up the many lawsuits filed in the U.S. involving bleeding deaths and injuries from the drug Xarelto.
The Court presiding over all the consolidated federal lawsuits related to Xarelto bleeding injuries has appointed lead counsel for the Plaintiffs’ Steering Committee. In Pretrial Order #7 signed by the Hon. Eldon E. Fallon, both Brian H. Barr of the Levin Papantonio law firm and Andy D. Birchfield of the Beasley Allen law firm were appointed as co-lead counsel to head a core group of twelve law firms that will litigate the case on behalf of injured plaintiffs. Cases involving bleeding injuries suffered by patients taking the Xarelto blood thinning medication filed against Johnson & Johnson and Bayer were previously consolidated before Judge Fallon into one federal action known as MDL 2592. Defendants include three German-based Bayer entities – Bayer HealthCare AG, Bayer Pharma AG, and Bayer AG.
Asked for comment, lead attorney Brian Barr said, “We look forward to the formal discovery process to get to the truth. The PSC will be reviewing company documents and will be seeking to take depositions of company officials.” While the litigation process is already underway, Plaintiffs are still coming forward with claims of serious bleeding injuries and even deaths that occurred while on the Xarelto medication. “Our experience with litigating the Pradaxa lawsuits (also a blood thinner) will give us a good head start in the discovery process,” attorney Barr added. The Court overseeing the consolidated Xarelto lawsuits is located in the Eastern District of Louisiana.
-
Bayer, J&J Begin Xarelto Study, Bleeding Lawsuits Consolidated
Feb 17, 2015 | Drug Watch
By Michelle Llamas
Bayer and Johnson & Johnson announced late last month they will push for additional Food and Drug Administration (FDA) approvals for the blockbuster blood-thinner Xarelto, even as two U.S. courts consolidated bleeding lawsuits against both companies.
Part of a class of new anticoagulants called Factor Xa inhibitors, the drug officially overtook its classmates and captured the largest share of the market thanks to its array of approved uses.
The popular blood thinner pulled in $1.5 billion in sales last year, and now, the drug’s makers want to pursue approvals for stroke patients, according to Fierce Pharma Marketing. The medication is facing off against a mainstay of stroke prevention: aspirin.
The latest push for additional federal approval comes amid concerns over a lack of antidote to stop potentially fatal bleeds and an increased number of lawsuits state and federal courts.
A new 7,000-patient trial — called the NAVIGATE-ESUS study — will focus on the effectiveness of Xarelto vs. aspirin in preventing subsequent strokes. Approximately 300,000 people in North America and Europe suffer these strokes annually, potentially broadening Xarelto’s reach, if it gains a wider approval.Xarelto Could Overtake Warfarin
J&J CEO Alex Gorsky said Xarelto already has as customers one-third of former warfarin users and that the medication may be poised to take the remaining two thirds if it gains extra approvals, according to Fierce Pharma Marketing. The company touts Xarelto as having the lowest out-of-pocket costs for patients of all the new blood thinners.
Gorsky didn’t comment on the recent Xarelto lawsuit consolidations in Louisiana and Philadelphia, where a growing number of plaintiffs say drugmakers failed to warn them that Xarelto increasing the risk of severe bleeding.Lead Lawyers Appointed in Xarelto Multidistrict Litigation
As Bayer and J&J pursue more studies, plaintiffs continue to file lawsuits against the Big Pharma giants. In December and January, judges in Louisiana and Pennsylvania gathered several cases into multidistrict litigation (MDL) and a mass tort program, respectively.
Collectively, more than 100 lawsuits filed by patients and their families claiming Xarelto caused serious health problems – and death, in some cases – now await trial. The lawsuits also claim that Xarelto’s lack of bleeding antidote makes the drug more dangerous.
The next step in the MDL process is the appointment of a plaintiff’s steering committee.
Judge Eldon E. Fallon of the U.S. District Court for the Eastern District of Louisiana appointed a 12-member Plaintiffs’ Steering Committee to be headed by Andy Birchfield, Jr. and Brian H. Barr, the co-lead counsels on the cases. Birchfield is from Beasley Allen in Montgomery, Alabama, Barr from Levin, Papantonio in Pensacola, Florida. Also on the steering committee:
Ellen Relkin, Weitz & Luxenberg, New York
Bradley Honnald, Bartimus Frickleton, Kansas City
Frederick Longer, Levi, Fishbein, Sedran & Berman, Philadelphia
Russell Abney, Ferrer, Poirot & Wansbrough, Atlanta
Dianne Nast, Nast Law, Philadelphia
Roger Denton, Schlicter, Bogard & Denton, St. Louis
Sindhu Daniel, SeegerWeiss, Newark, New Jersey
Michael Goetz, Morgan and Morgan, Tampa
Neil Overholtz, Aylstock, Witkin, Kreis & Overholtz, PensacolaThe steering committee will ensure that litigation of multiple cases moves as swiftly and efficiently as possible, including conducting discovery, exploring settlement options and coordinating trial team selection.
In a hearing last month, Fallon said about 30 percent of U.S.-filed Xarelto civil claims are in an MDL.
-
Has XARELTO Litigation Been Consolidated?
Feb 13, 2015 | Zoll, Kranz & Borgess LLC
The drug Xarelto (rivaroxaban) is a blood thinner commonly used to treat atrial fibrillation, and on patients who have had hip or knee replacement surgery. However, it has been linked to uncontrolled internal bleeding, particularly gastrointestinal bleeding events.
Where other blood thinners like Warfarin may have antidotes to control bleeding events, Xarelto does not. This has allegedly led to cases where patients have been seriously injured or killed from bleeding out.
Last year, Bloomberg reported that 65 deaths had been linked to Xarelto, and that lawsuits were filed in at least 10 federal courts against manufacturer Johnson & Johnson.Xarelto Lawsuits Consolidated
Recently, an Administrative Law Judge (ALJ) in Pennsylvania issued an order consolidating 75 Xarelto lawsuits together into one mass tort docket in a state court.
Attorneys for the plaintiffs were happy with the ruling, as they said that it would promote an easier trial process by eliminating duplicative evidence during pretrial proceedings, potentially speeding up the process.
This is not the first round of Xarelto litigation to be consolidated. Late last year, a US Judicial Panel on Multidistrict Litigation consolidated numerous lawsuits for multidistrict litigation (MDL) in a Louisiana federal court.
If you have questions about the differences between class action cases and MDLs, or mass tort cases in general, you canclick here.
The type of lawsuit you are involved in can have an impact on the amount of damages you may be able to recover. Our attorneys use cutting-edge technology to investigate injury claims and provide clients with the representation they need to be successful, no matter the type of case.
-
XARELTO Cases Adding Plaintiffs
Feb 14, 2015 | Meyerkord & Meyerkord LLC
Janssen Research and Development and Bayer Healthcare Pharmaceuticals are continuing to be named in lawsuits for their negligence by users of the drug Xarelto. The defendants are the makers of the anticoagulant, Xarelto, and are claiming their product is the best anticoagulant in the market due to its' convenience. Xarelto lawsuits have recently been consolidated due to the growing number of cases filed.
Xarelto is a blood thinner being heavily marketed for its convenience due to the low maintenance of the drug. Previous blood thinners, such as Warfarin, require lifestyle changes such as diet restrictions and continuous monitoring through regular blood tests. Xarelto does not require any of these changes making it more appealing to a patient. One major difference between Warfarin and Xarelto, is that Xarelto does not have an antidote to stop the thinning of the blood to prevent users from bleeding uncontrollably.
The manufacturers have failed to warn users about the risks associated with Xarelto, including the lack of an antidote. Plaintiffs have sustained injuries from internal bleeding, uncontrollable bleeding, and death. They are claiming the manufacturers are providing false advertisement and marketing by misleading patients to believe Xarelto is safe.
The skilled St. Louis personal injury lawyers at Meyerkord & Meyerkord are dedicated professionals with over 100 years of combined experience in drug liability cases, and are ready to serve you. Our personal injury attorneys are licensed in Missouri and Illinois. We have logged thousands of hours on the phone with insurance companies and recovered millions of dollars for medical bills, pain and suffering, and property damage. Likewise, when represented by Meyerkord & Meyerkord, you will receive the personal attention and excellent service that you deserve while we work tirelessly for you to get you the financial compensation you deserve.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blogs
Steering Committee
MDL Consolidation
Full Text of Stories Below
Add recipients
Suggested